3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Sarcoma
3
Insulin-Like Growth Factor I, Resistance To
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Adenocarcinoma
2
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Pleural Effusion, Malignant
1
Neuroectodermal Tumors, Primitive
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Jaundice
1
Gastrointestinal Neoplasms
1
Endocrine Gland Neoplasms
1
Carcinoid Tumor
1
Askin Tumor
1
Interventions
Carboplatin
98
Pemetrexed
70
pembrolizumab
68
Cisplatin
59
Paclitaxel
54
Docetaxel
45
Gemcitabine
37
Erlotinib Hydrochloride
24
Nivolumab
23
osimertinib
17
Bevacizumab
17
durvalumab
14
Cetuximab
13
130-nm albumin-bound paclitaxel
13
Gefitinib
11
Etoposide
11
Drug Therapy
11
Ipilimumab
9
Injections
9
Albumin-Bound Paclitaxel
9
Vinorelbine
8
Radiotherapy
8
motexafin gadolinium
7
capmatinib
7
atezolizumab
7
epacadostat
6
Taxes
6
Cyclophosphamide
6
vandetanib
5
entinostat
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lung Neoplasms
×
ganitumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts